Review



human ccrcc cell lines 786 o  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC human ccrcc cell lines 786 o
    MUC3A is aberrantly upregulated in ccRCC and associated with poor prognosis. (A) Pan-cancer analysis of MUC3A expression across multiple tumor types based on TCGA data, generated using the GEPIA2 platform. Gene expression values are presented as log2(TPM + 1). (B) Differential expression of MUC3A in tumor and normal samples from the TCGA-KIRC cohort (523 tumor samples vs. 72 normal samples). *P<0.05. (C) Western blotting of MUC3A protein expression in HK-2 and RPTEC/TERT1 non-malignant renal epithelial cell lines and ccRCC cell lines (CAKI-1, <t>OSRC-2,</t> <t>786-O</t> and ACHN). GAPDH was used as a loading control. (D) Western blotting of MUC3A knockdown efficiency in 786-O and OSRC-2 cells following transient transfection with three independent siRNAs targeting MUC3A. si-2 was selected for subsequent functional experiments due to its superior knockdown efficiency. (E) Kaplan-Meier OS analysis of ccRCC patients stratified into high- and low-MUC3A expression groups using the GEPIA2 platform. (F) Kaplan-Meier DFS analysis of ccRCC patients based on MUC3A expression levels. Data are derived from TCGA unless otherwise indicated. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; TPM, transcripts per million; KIRC, kidney renal clear cell carcinoma; OS, overall survival; DFS, disease-free survival; siRNA, small interfering RNA; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; si-1/si-2/si-3, three independent siRNAs targeting MUC3A.
    Human Ccrcc Cell Lines 786 O, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 2275 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccrcc+cell+lines+786+o/786-O/pmc13107098-28-0-46
    Average 99 stars, based on 2275 article reviews
    human ccrcc cell lines 786 o - by Bioz Stars, 2026-10
    99/100 stars

    Images

    1) Product Images from "Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK-STAT pathway"

    Article Title: Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK-STAT pathway

    Journal: Oncology Reports

    doi: 10.3892/or.2026.9119

    MUC3A is aberrantly upregulated in ccRCC and associated with poor prognosis. (A) Pan-cancer analysis of MUC3A expression across multiple tumor types based on TCGA data, generated using the GEPIA2 platform. Gene expression values are presented as log2(TPM + 1). (B) Differential expression of MUC3A in tumor and normal samples from the TCGA-KIRC cohort (523 tumor samples vs. 72 normal samples). *P<0.05. (C) Western blotting of MUC3A protein expression in HK-2 and RPTEC/TERT1 non-malignant renal epithelial cell lines and ccRCC cell lines (CAKI-1, OSRC-2, 786-O and ACHN). GAPDH was used as a loading control. (D) Western blotting of MUC3A knockdown efficiency in 786-O and OSRC-2 cells following transient transfection with three independent siRNAs targeting MUC3A. si-2 was selected for subsequent functional experiments due to its superior knockdown efficiency. (E) Kaplan-Meier OS analysis of ccRCC patients stratified into high- and low-MUC3A expression groups using the GEPIA2 platform. (F) Kaplan-Meier DFS analysis of ccRCC patients based on MUC3A expression levels. Data are derived from TCGA unless otherwise indicated. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; TPM, transcripts per million; KIRC, kidney renal clear cell carcinoma; OS, overall survival; DFS, disease-free survival; siRNA, small interfering RNA; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; si-1/si-2/si-3, three independent siRNAs targeting MUC3A.
    Figure Legend Snippet: MUC3A is aberrantly upregulated in ccRCC and associated with poor prognosis. (A) Pan-cancer analysis of MUC3A expression across multiple tumor types based on TCGA data, generated using the GEPIA2 platform. Gene expression values are presented as log2(TPM + 1). (B) Differential expression of MUC3A in tumor and normal samples from the TCGA-KIRC cohort (523 tumor samples vs. 72 normal samples). *P<0.05. (C) Western blotting of MUC3A protein expression in HK-2 and RPTEC/TERT1 non-malignant renal epithelial cell lines and ccRCC cell lines (CAKI-1, OSRC-2, 786-O and ACHN). GAPDH was used as a loading control. (D) Western blotting of MUC3A knockdown efficiency in 786-O and OSRC-2 cells following transient transfection with three independent siRNAs targeting MUC3A. si-2 was selected for subsequent functional experiments due to its superior knockdown efficiency. (E) Kaplan-Meier OS analysis of ccRCC patients stratified into high- and low-MUC3A expression groups using the GEPIA2 platform. (F) Kaplan-Meier DFS analysis of ccRCC patients based on MUC3A expression levels. Data are derived from TCGA unless otherwise indicated. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; TPM, transcripts per million; KIRC, kidney renal clear cell carcinoma; OS, overall survival; DFS, disease-free survival; siRNA, small interfering RNA; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; si-1/si-2/si-3, three independent siRNAs targeting MUC3A.

    Techniques Used: Expressing, Generated, Gene Expression, Quantitative Proteomics, Western Blot, Control, Knockdown, Transfection, Functional Assay, Derivative Assay, Small Interfering RNA

    MUC3A knockdown suppresses proliferation and promotes apoptosis in ccRCC cells. (A and B) Cell proliferation of 786-O and OSRC-2 cells following transfection with si-MUC3A or si-Ctrl, as assessed by CCK-8 assays at the indicated time points. (C and D) Colony formation assays showing the clonogenic capacity of 786-O and OSRC-2 cells following MUC3A knockdown. Representative images and quantitative analysis are shown. (E and F) Flow cytometric analysis of apoptosis in 786-O and OSRC-2 cells using Annexin V-FITC/PI staining following MUC3A silencing. Representative dot plots and corresponding quantitative results are presented. All experiments were performed with at least three independent biological replicates (n≥3). Data are presented as the mean ± SD. Statistical significance was determined using a two-tailed unpaired Student's t-test. *P<0.05, **P<0.01 and ***P<0.001. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; CCK-8, Cell Counting Kit-8; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; PI, propidium iodide; SD, standard deviation; ns, not significant.
    Figure Legend Snippet: MUC3A knockdown suppresses proliferation and promotes apoptosis in ccRCC cells. (A and B) Cell proliferation of 786-O and OSRC-2 cells following transfection with si-MUC3A or si-Ctrl, as assessed by CCK-8 assays at the indicated time points. (C and D) Colony formation assays showing the clonogenic capacity of 786-O and OSRC-2 cells following MUC3A knockdown. Representative images and quantitative analysis are shown. (E and F) Flow cytometric analysis of apoptosis in 786-O and OSRC-2 cells using Annexin V-FITC/PI staining following MUC3A silencing. Representative dot plots and corresponding quantitative results are presented. All experiments were performed with at least three independent biological replicates (n≥3). Data are presented as the mean ± SD. Statistical significance was determined using a two-tailed unpaired Student's t-test. *P<0.05, **P<0.01 and ***P<0.001. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; CCK-8, Cell Counting Kit-8; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; PI, propidium iodide; SD, standard deviation; ns, not significant.

    Techniques Used: Knockdown, Transfection, CCK-8 Assay, Staining, Two Tailed Test, Cell Counting, Control, Standard Deviation

    MUC3A knockdown inhibits the migration and invasion of ccRCC cells. (A) Transwell migration assays showing the migratory capacity of 786-O and OSRC-2 cells following MUC3A knockdown. Quantitative analysis is shown on the right. (B) Transwell invasion assays performed using Matrigel ® -coated chambers to assess the invasive potential of ccRCC cells after MUC3A silencing. (C) Wound healing assays demonstrating delayed wound closure in 786-O and OSRC-2 cells transfected with si-MUC3A compared with si-Ctrl at 24 h. Representative images and quantitative analyses are shown. Scale bar, 100 µm. All experiments were conducted with at least three independent biological replicates. Data are expressed as the mean ± SD. **P<0.01 and ***P<0.001. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; SD, standard deviation.
    Figure Legend Snippet: MUC3A knockdown inhibits the migration and invasion of ccRCC cells. (A) Transwell migration assays showing the migratory capacity of 786-O and OSRC-2 cells following MUC3A knockdown. Quantitative analysis is shown on the right. (B) Transwell invasion assays performed using Matrigel ® -coated chambers to assess the invasive potential of ccRCC cells after MUC3A silencing. (C) Wound healing assays demonstrating delayed wound closure in 786-O and OSRC-2 cells transfected with si-MUC3A compared with si-Ctrl at 24 h. Representative images and quantitative analyses are shown. Scale bar, 100 µm. All experiments were conducted with at least three independent biological replicates. Data are expressed as the mean ± SD. **P<0.01 and ***P<0.001. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; SD, standard deviation.

    Techniques Used: Knockdown, Migration, Transfection, Control, Standard Deviation

    MUC3A is associated with the activation of the JAK-STAT signaling pathway in ccRCC. (A) KEGG pathway enrichment analysis of genes associated with MUC3A expression based on TCGA-KIRC transcriptomic data. (B) GSEA showing significant enrichment of the JAK-STAT signaling pathway in ccRCC samples with a high MUC3A expression. (C and D) Western blotting of total and phosphorylated JAK1, JAK2 and STAT3 in 786-O and OSRC-2 cells following MUC3A knockdown. (E) Western blotting showing that STAT3 activation by Colivelin TFA restores p-STAT3 levels in si-MUC3A-transfected 786-O and OSRC-2 cells, accompanied by increased Bcl-2 and decreased cleaved caspase-3 expression. (F) Western blotting of apoptosis-related proteins Bcl-2 and cleaved caspase-3 following MUC3A silencing. GAPDH served as a loading control. All western blotting experiments were repeated independently at least three times. MUC3A, mucin 3A; JAK, Janus kinase; STAT, signal transducer and activator of transcription; ccRCC, clear cell renal cell carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GSEA, gene set enrichment analysis; TFA, trifluoroacetate; p-, phosphorylated.
    Figure Legend Snippet: MUC3A is associated with the activation of the JAK-STAT signaling pathway in ccRCC. (A) KEGG pathway enrichment analysis of genes associated with MUC3A expression based on TCGA-KIRC transcriptomic data. (B) GSEA showing significant enrichment of the JAK-STAT signaling pathway in ccRCC samples with a high MUC3A expression. (C and D) Western blotting of total and phosphorylated JAK1, JAK2 and STAT3 in 786-O and OSRC-2 cells following MUC3A knockdown. (E) Western blotting showing that STAT3 activation by Colivelin TFA restores p-STAT3 levels in si-MUC3A-transfected 786-O and OSRC-2 cells, accompanied by increased Bcl-2 and decreased cleaved caspase-3 expression. (F) Western blotting of apoptosis-related proteins Bcl-2 and cleaved caspase-3 following MUC3A silencing. GAPDH served as a loading control. All western blotting experiments were repeated independently at least three times. MUC3A, mucin 3A; JAK, Janus kinase; STAT, signal transducer and activator of transcription; ccRCC, clear cell renal cell carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GSEA, gene set enrichment analysis; TFA, trifluoroacetate; p-, phosphorylated.

    Techniques Used: Activation Assay, Expressing, Western Blot, Knockdown, Transfection, Control

    STAT3 activation partially rescues the effects of MUC3A knockdown in ccRCC cells. (A and B) CCK-8 assays showing that treatment with the STAT3 agonist Colivelin TFA partially restored the proliferation of 786-O and OSRC-2 cells following MUC3A knockdown. (C-F) Flow cytometric analysis demonstrating that Colivelin TFA treatment reverses the apoptosis-promoting effect induced by MUC3A silencing in ccRCC cells. Data are presented as the mean ± SD from at least three independent biological replicates. Statistical significance was assessed using Student's t-test or one-way ANOVA as appropriate. *P<0.05, **P<0.01 and ***P<0.001. STAT3, signal transducer and activator of transcription 3; TFA, trifluoroacetate; MUC3A, mucin 3A; CCK-8, Cell Counting Kit-8; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; SD, standard deviation; ANOVA, analysis of variance.
    Figure Legend Snippet: STAT3 activation partially rescues the effects of MUC3A knockdown in ccRCC cells. (A and B) CCK-8 assays showing that treatment with the STAT3 agonist Colivelin TFA partially restored the proliferation of 786-O and OSRC-2 cells following MUC3A knockdown. (C-F) Flow cytometric analysis demonstrating that Colivelin TFA treatment reverses the apoptosis-promoting effect induced by MUC3A silencing in ccRCC cells. Data are presented as the mean ± SD from at least three independent biological replicates. Statistical significance was assessed using Student's t-test or one-way ANOVA as appropriate. *P<0.05, **P<0.01 and ***P<0.001. STAT3, signal transducer and activator of transcription 3; TFA, trifluoroacetate; MUC3A, mucin 3A; CCK-8, Cell Counting Kit-8; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; SD, standard deviation; ANOVA, analysis of variance.

    Techniques Used: Activation Assay, Knockdown, CCK-8 Assay, Cell Counting, Control, Standard Deviation

    Related Articles

    Cell Culture:

    Article Title: PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma.
    Article Snippet: .. Cell Culture and siRNA Transfection The human ccRCC cell lines 786-O, Caki-1, and OSRC-2, and the normal renal cell lines ACCEPTED MANUSCRIPT AR TIC LE IN PR ES S ARTICLE IN PRESS HEK-293 and HK-2 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). .. All cells were maintained in DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) in a humidified incubator at 37°C with 5% CO2.

    Transfection:

    Article Title: PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma.
    Article Snippet: .. Cell Culture and siRNA Transfection The human ccRCC cell lines 786-O, Caki-1, and OSRC-2, and the normal renal cell lines ACCEPTED MANUSCRIPT AR TIC LE IN PR ES S ARTICLE IN PRESS HEK-293 and HK-2 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). .. All cells were maintained in DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) in a humidified incubator at 37°C with 5% CO2.



    Similar Products

    99
    ATCC human ccrcc cell lines 786 o
    MUC3A is aberrantly upregulated in ccRCC and associated with poor prognosis. (A) Pan-cancer analysis of MUC3A expression across multiple tumor types based on TCGA data, generated using the GEPIA2 platform. Gene expression values are presented as log2(TPM + 1). (B) Differential expression of MUC3A in tumor and normal samples from the TCGA-KIRC cohort (523 tumor samples vs. 72 normal samples). *P<0.05. (C) Western blotting of MUC3A protein expression in HK-2 and RPTEC/TERT1 non-malignant renal epithelial cell lines and ccRCC cell lines (CAKI-1, <t>OSRC-2,</t> <t>786-O</t> and ACHN). GAPDH was used as a loading control. (D) Western blotting of MUC3A knockdown efficiency in 786-O and OSRC-2 cells following transient transfection with three independent siRNAs targeting MUC3A. si-2 was selected for subsequent functional experiments due to its superior knockdown efficiency. (E) Kaplan-Meier OS analysis of ccRCC patients stratified into high- and low-MUC3A expression groups using the GEPIA2 platform. (F) Kaplan-Meier DFS analysis of ccRCC patients based on MUC3A expression levels. Data are derived from TCGA unless otherwise indicated. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; TPM, transcripts per million; KIRC, kidney renal clear cell carcinoma; OS, overall survival; DFS, disease-free survival; siRNA, small interfering RNA; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; si-1/si-2/si-3, three independent siRNAs targeting MUC3A.
    Human Ccrcc Cell Lines 786 O, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccrcc+cell+lines+786+o/786-O/pmc13107098-28-0-46
    Average 99 stars, based on 1 article reviews
    human ccrcc cell lines 786 o - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    ATCC human ccrcc cell line 786 o
    MUC3A is aberrantly upregulated in ccRCC and associated with poor prognosis. (A) Pan-cancer analysis of MUC3A expression across multiple tumor types based on TCGA data, generated using the GEPIA2 platform. Gene expression values are presented as log2(TPM + 1). (B) Differential expression of MUC3A in tumor and normal samples from the TCGA-KIRC cohort (523 tumor samples vs. 72 normal samples). *P<0.05. (C) Western blotting of MUC3A protein expression in HK-2 and RPTEC/TERT1 non-malignant renal epithelial cell lines and ccRCC cell lines (CAKI-1, <t>OSRC-2,</t> <t>786-O</t> and ACHN). GAPDH was used as a loading control. (D) Western blotting of MUC3A knockdown efficiency in 786-O and OSRC-2 cells following transient transfection with three independent siRNAs targeting MUC3A. si-2 was selected for subsequent functional experiments due to its superior knockdown efficiency. (E) Kaplan-Meier OS analysis of ccRCC patients stratified into high- and low-MUC3A expression groups using the GEPIA2 platform. (F) Kaplan-Meier DFS analysis of ccRCC patients based on MUC3A expression levels. Data are derived from TCGA unless otherwise indicated. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; TPM, transcripts per million; KIRC, kidney renal clear cell carcinoma; OS, overall survival; DFS, disease-free survival; siRNA, small interfering RNA; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; si-1/si-2/si-3, three independent siRNAs targeting MUC3A.
    Human Ccrcc Cell Line 786 O, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccrcc+cell+lines+786+o/786-O/pm42189461-42-1-31
    Average 99 stars, based on 1 article reviews
    human ccrcc cell line 786 o - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    86
    Procell Inc human ccrcc cell lines 786 o
    MUC3A is aberrantly upregulated in ccRCC and associated with poor prognosis. (A) Pan-cancer analysis of MUC3A expression across multiple tumor types based on TCGA data, generated using the GEPIA2 platform. Gene expression values are presented as log2(TPM + 1). (B) Differential expression of MUC3A in tumor and normal samples from the TCGA-KIRC cohort (523 tumor samples vs. 72 normal samples). *P<0.05. (C) Western blotting of MUC3A protein expression in HK-2 and RPTEC/TERT1 non-malignant renal epithelial cell lines and ccRCC cell lines (CAKI-1, <t>OSRC-2,</t> <t>786-O</t> and ACHN). GAPDH was used as a loading control. (D) Western blotting of MUC3A knockdown efficiency in 786-O and OSRC-2 cells following transient transfection with three independent siRNAs targeting MUC3A. si-2 was selected for subsequent functional experiments due to its superior knockdown efficiency. (E) Kaplan-Meier OS analysis of ccRCC patients stratified into high- and low-MUC3A expression groups using the GEPIA2 platform. (F) Kaplan-Meier DFS analysis of ccRCC patients based on MUC3A expression levels. Data are derived from TCGA unless otherwise indicated. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; TPM, transcripts per million; KIRC, kidney renal clear cell carcinoma; OS, overall survival; DFS, disease-free survival; siRNA, small interfering RNA; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; si-1/si-2/si-3, three independent siRNAs targeting MUC3A.
    Human Ccrcc Cell Lines 786 O, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccrcc+cell+lines+786+o/3+carcinoma+cell+chorionic+human+jeg/pm41258382-80-0-10
    Average 86 stars, based on 1 article reviews
    human ccrcc cell lines 786 o - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    99
    ATCC human ccrcc cell lines 786 o 769 p
    MUC3A is aberrantly upregulated in ccRCC and associated with poor prognosis. (A) Pan-cancer analysis of MUC3A expression across multiple tumor types based on TCGA data, generated using the GEPIA2 platform. Gene expression values are presented as log2(TPM + 1). (B) Differential expression of MUC3A in tumor and normal samples from the TCGA-KIRC cohort (523 tumor samples vs. 72 normal samples). *P<0.05. (C) Western blotting of MUC3A protein expression in HK-2 and RPTEC/TERT1 non-malignant renal epithelial cell lines and ccRCC cell lines (CAKI-1, <t>OSRC-2,</t> <t>786-O</t> and ACHN). GAPDH was used as a loading control. (D) Western blotting of MUC3A knockdown efficiency in 786-O and OSRC-2 cells following transient transfection with three independent siRNAs targeting MUC3A. si-2 was selected for subsequent functional experiments due to its superior knockdown efficiency. (E) Kaplan-Meier OS analysis of ccRCC patients stratified into high- and low-MUC3A expression groups using the GEPIA2 platform. (F) Kaplan-Meier DFS analysis of ccRCC patients based on MUC3A expression levels. Data are derived from TCGA unless otherwise indicated. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; TPM, transcripts per million; KIRC, kidney renal clear cell carcinoma; OS, overall survival; DFS, disease-free survival; siRNA, small interfering RNA; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; si-1/si-2/si-3, three independent siRNAs targeting MUC3A.
    Human Ccrcc Cell Lines 786 O 769 P, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccrcc+cell+lines+786+o/786-O/pmc12350486-60-1-14
    Average 99 stars, based on 1 article reviews
    human ccrcc cell lines 786 o 769 p - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    Image Search Results


    MUC3A is aberrantly upregulated in ccRCC and associated with poor prognosis. (A) Pan-cancer analysis of MUC3A expression across multiple tumor types based on TCGA data, generated using the GEPIA2 platform. Gene expression values are presented as log2(TPM + 1). (B) Differential expression of MUC3A in tumor and normal samples from the TCGA-KIRC cohort (523 tumor samples vs. 72 normal samples). *P<0.05. (C) Western blotting of MUC3A protein expression in HK-2 and RPTEC/TERT1 non-malignant renal epithelial cell lines and ccRCC cell lines (CAKI-1, OSRC-2, 786-O and ACHN). GAPDH was used as a loading control. (D) Western blotting of MUC3A knockdown efficiency in 786-O and OSRC-2 cells following transient transfection with three independent siRNAs targeting MUC3A. si-2 was selected for subsequent functional experiments due to its superior knockdown efficiency. (E) Kaplan-Meier OS analysis of ccRCC patients stratified into high- and low-MUC3A expression groups using the GEPIA2 platform. (F) Kaplan-Meier DFS analysis of ccRCC patients based on MUC3A expression levels. Data are derived from TCGA unless otherwise indicated. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; TPM, transcripts per million; KIRC, kidney renal clear cell carcinoma; OS, overall survival; DFS, disease-free survival; siRNA, small interfering RNA; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; si-1/si-2/si-3, three independent siRNAs targeting MUC3A.

    Journal: Oncology Reports

    Article Title: Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK-STAT pathway

    doi: 10.3892/or.2026.9119

    Figure Lengend Snippet: MUC3A is aberrantly upregulated in ccRCC and associated with poor prognosis. (A) Pan-cancer analysis of MUC3A expression across multiple tumor types based on TCGA data, generated using the GEPIA2 platform. Gene expression values are presented as log2(TPM + 1). (B) Differential expression of MUC3A in tumor and normal samples from the TCGA-KIRC cohort (523 tumor samples vs. 72 normal samples). *P<0.05. (C) Western blotting of MUC3A protein expression in HK-2 and RPTEC/TERT1 non-malignant renal epithelial cell lines and ccRCC cell lines (CAKI-1, OSRC-2, 786-O and ACHN). GAPDH was used as a loading control. (D) Western blotting of MUC3A knockdown efficiency in 786-O and OSRC-2 cells following transient transfection with three independent siRNAs targeting MUC3A. si-2 was selected for subsequent functional experiments due to its superior knockdown efficiency. (E) Kaplan-Meier OS analysis of ccRCC patients stratified into high- and low-MUC3A expression groups using the GEPIA2 platform. (F) Kaplan-Meier DFS analysis of ccRCC patients based on MUC3A expression levels. Data are derived from TCGA unless otherwise indicated. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GEPIA2, Gene Expression Profiling Interactive Analysis 2; TPM, transcripts per million; KIRC, kidney renal clear cell carcinoma; OS, overall survival; DFS, disease-free survival; siRNA, small interfering RNA; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; si-1/si-2/si-3, three independent siRNAs targeting MUC3A.

    Article Snippet: Human ccRCC cell lines 786-O (cat. no. CL-0010), OSRC-2 (cat. no. CL-0177), Caki-1 (cat. no. CL-0052) and ACHN (cat. no. CL-0021), as well as non-malignant renal epithelial cells HK-2 (cat. no. CL-0109; all from Procell Life Science & Technology Co., Ltd.) and RPTEC/TERT1 (cat. no. CRL-4031; American Type Culture Collection), were used in the present study.

    Techniques: Expressing, Generated, Gene Expression, Quantitative Proteomics, Western Blot, Control, Knockdown, Transfection, Functional Assay, Derivative Assay, Small Interfering RNA

    MUC3A knockdown suppresses proliferation and promotes apoptosis in ccRCC cells. (A and B) Cell proliferation of 786-O and OSRC-2 cells following transfection with si-MUC3A or si-Ctrl, as assessed by CCK-8 assays at the indicated time points. (C and D) Colony formation assays showing the clonogenic capacity of 786-O and OSRC-2 cells following MUC3A knockdown. Representative images and quantitative analysis are shown. (E and F) Flow cytometric analysis of apoptosis in 786-O and OSRC-2 cells using Annexin V-FITC/PI staining following MUC3A silencing. Representative dot plots and corresponding quantitative results are presented. All experiments were performed with at least three independent biological replicates (n≥3). Data are presented as the mean ± SD. Statistical significance was determined using a two-tailed unpaired Student's t-test. *P<0.05, **P<0.01 and ***P<0.001. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; CCK-8, Cell Counting Kit-8; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; PI, propidium iodide; SD, standard deviation; ns, not significant.

    Journal: Oncology Reports

    Article Title: Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK-STAT pathway

    doi: 10.3892/or.2026.9119

    Figure Lengend Snippet: MUC3A knockdown suppresses proliferation and promotes apoptosis in ccRCC cells. (A and B) Cell proliferation of 786-O and OSRC-2 cells following transfection with si-MUC3A or si-Ctrl, as assessed by CCK-8 assays at the indicated time points. (C and D) Colony formation assays showing the clonogenic capacity of 786-O and OSRC-2 cells following MUC3A knockdown. Representative images and quantitative analysis are shown. (E and F) Flow cytometric analysis of apoptosis in 786-O and OSRC-2 cells using Annexin V-FITC/PI staining following MUC3A silencing. Representative dot plots and corresponding quantitative results are presented. All experiments were performed with at least three independent biological replicates (n≥3). Data are presented as the mean ± SD. Statistical significance was determined using a two-tailed unpaired Student's t-test. *P<0.05, **P<0.01 and ***P<0.001. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; CCK-8, Cell Counting Kit-8; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; PI, propidium iodide; SD, standard deviation; ns, not significant.

    Article Snippet: Human ccRCC cell lines 786-O (cat. no. CL-0010), OSRC-2 (cat. no. CL-0177), Caki-1 (cat. no. CL-0052) and ACHN (cat. no. CL-0021), as well as non-malignant renal epithelial cells HK-2 (cat. no. CL-0109; all from Procell Life Science & Technology Co., Ltd.) and RPTEC/TERT1 (cat. no. CRL-4031; American Type Culture Collection), were used in the present study.

    Techniques: Knockdown, Transfection, CCK-8 Assay, Staining, Two Tailed Test, Cell Counting, Control, Standard Deviation

    MUC3A knockdown inhibits the migration and invasion of ccRCC cells. (A) Transwell migration assays showing the migratory capacity of 786-O and OSRC-2 cells following MUC3A knockdown. Quantitative analysis is shown on the right. (B) Transwell invasion assays performed using Matrigel ® -coated chambers to assess the invasive potential of ccRCC cells after MUC3A silencing. (C) Wound healing assays demonstrating delayed wound closure in 786-O and OSRC-2 cells transfected with si-MUC3A compared with si-Ctrl at 24 h. Representative images and quantitative analyses are shown. Scale bar, 100 µm. All experiments were conducted with at least three independent biological replicates. Data are expressed as the mean ± SD. **P<0.01 and ***P<0.001. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; SD, standard deviation.

    Journal: Oncology Reports

    Article Title: Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK-STAT pathway

    doi: 10.3892/or.2026.9119

    Figure Lengend Snippet: MUC3A knockdown inhibits the migration and invasion of ccRCC cells. (A) Transwell migration assays showing the migratory capacity of 786-O and OSRC-2 cells following MUC3A knockdown. Quantitative analysis is shown on the right. (B) Transwell invasion assays performed using Matrigel ® -coated chambers to assess the invasive potential of ccRCC cells after MUC3A silencing. (C) Wound healing assays demonstrating delayed wound closure in 786-O and OSRC-2 cells transfected with si-MUC3A compared with si-Ctrl at 24 h. Representative images and quantitative analyses are shown. Scale bar, 100 µm. All experiments were conducted with at least three independent biological replicates. Data are expressed as the mean ± SD. **P<0.01 and ***P<0.001. MUC3A, mucin 3A; ccRCC, clear cell renal cell carcinoma; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; SD, standard deviation.

    Article Snippet: Human ccRCC cell lines 786-O (cat. no. CL-0010), OSRC-2 (cat. no. CL-0177), Caki-1 (cat. no. CL-0052) and ACHN (cat. no. CL-0021), as well as non-malignant renal epithelial cells HK-2 (cat. no. CL-0109; all from Procell Life Science & Technology Co., Ltd.) and RPTEC/TERT1 (cat. no. CRL-4031; American Type Culture Collection), were used in the present study.

    Techniques: Knockdown, Migration, Transfection, Control, Standard Deviation

    MUC3A is associated with the activation of the JAK-STAT signaling pathway in ccRCC. (A) KEGG pathway enrichment analysis of genes associated with MUC3A expression based on TCGA-KIRC transcriptomic data. (B) GSEA showing significant enrichment of the JAK-STAT signaling pathway in ccRCC samples with a high MUC3A expression. (C and D) Western blotting of total and phosphorylated JAK1, JAK2 and STAT3 in 786-O and OSRC-2 cells following MUC3A knockdown. (E) Western blotting showing that STAT3 activation by Colivelin TFA restores p-STAT3 levels in si-MUC3A-transfected 786-O and OSRC-2 cells, accompanied by increased Bcl-2 and decreased cleaved caspase-3 expression. (F) Western blotting of apoptosis-related proteins Bcl-2 and cleaved caspase-3 following MUC3A silencing. GAPDH served as a loading control. All western blotting experiments were repeated independently at least three times. MUC3A, mucin 3A; JAK, Janus kinase; STAT, signal transducer and activator of transcription; ccRCC, clear cell renal cell carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GSEA, gene set enrichment analysis; TFA, trifluoroacetate; p-, phosphorylated.

    Journal: Oncology Reports

    Article Title: Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK-STAT pathway

    doi: 10.3892/or.2026.9119

    Figure Lengend Snippet: MUC3A is associated with the activation of the JAK-STAT signaling pathway in ccRCC. (A) KEGG pathway enrichment analysis of genes associated with MUC3A expression based on TCGA-KIRC transcriptomic data. (B) GSEA showing significant enrichment of the JAK-STAT signaling pathway in ccRCC samples with a high MUC3A expression. (C and D) Western blotting of total and phosphorylated JAK1, JAK2 and STAT3 in 786-O and OSRC-2 cells following MUC3A knockdown. (E) Western blotting showing that STAT3 activation by Colivelin TFA restores p-STAT3 levels in si-MUC3A-transfected 786-O and OSRC-2 cells, accompanied by increased Bcl-2 and decreased cleaved caspase-3 expression. (F) Western blotting of apoptosis-related proteins Bcl-2 and cleaved caspase-3 following MUC3A silencing. GAPDH served as a loading control. All western blotting experiments were repeated independently at least three times. MUC3A, mucin 3A; JAK, Janus kinase; STAT, signal transducer and activator of transcription; ccRCC, clear cell renal cell carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes; TCGA, The Cancer Genome Atlas; KIRC, kidney renal clear cell carcinoma; GSEA, gene set enrichment analysis; TFA, trifluoroacetate; p-, phosphorylated.

    Article Snippet: Human ccRCC cell lines 786-O (cat. no. CL-0010), OSRC-2 (cat. no. CL-0177), Caki-1 (cat. no. CL-0052) and ACHN (cat. no. CL-0021), as well as non-malignant renal epithelial cells HK-2 (cat. no. CL-0109; all from Procell Life Science & Technology Co., Ltd.) and RPTEC/TERT1 (cat. no. CRL-4031; American Type Culture Collection), were used in the present study.

    Techniques: Activation Assay, Expressing, Western Blot, Knockdown, Transfection, Control

    STAT3 activation partially rescues the effects of MUC3A knockdown in ccRCC cells. (A and B) CCK-8 assays showing that treatment with the STAT3 agonist Colivelin TFA partially restored the proliferation of 786-O and OSRC-2 cells following MUC3A knockdown. (C-F) Flow cytometric analysis demonstrating that Colivelin TFA treatment reverses the apoptosis-promoting effect induced by MUC3A silencing in ccRCC cells. Data are presented as the mean ± SD from at least three independent biological replicates. Statistical significance was assessed using Student's t-test or one-way ANOVA as appropriate. *P<0.05, **P<0.01 and ***P<0.001. STAT3, signal transducer and activator of transcription 3; TFA, trifluoroacetate; MUC3A, mucin 3A; CCK-8, Cell Counting Kit-8; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; SD, standard deviation; ANOVA, analysis of variance.

    Journal: Oncology Reports

    Article Title: Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK-STAT pathway

    doi: 10.3892/or.2026.9119

    Figure Lengend Snippet: STAT3 activation partially rescues the effects of MUC3A knockdown in ccRCC cells. (A and B) CCK-8 assays showing that treatment with the STAT3 agonist Colivelin TFA partially restored the proliferation of 786-O and OSRC-2 cells following MUC3A knockdown. (C-F) Flow cytometric analysis demonstrating that Colivelin TFA treatment reverses the apoptosis-promoting effect induced by MUC3A silencing in ccRCC cells. Data are presented as the mean ± SD from at least three independent biological replicates. Statistical significance was assessed using Student's t-test or one-way ANOVA as appropriate. *P<0.05, **P<0.01 and ***P<0.001. STAT3, signal transducer and activator of transcription 3; TFA, trifluoroacetate; MUC3A, mucin 3A; CCK-8, Cell Counting Kit-8; si-MUC3A, MUC3A-targeting siRNA; si-Ctrl, non-targeting control siRNA; SD, standard deviation; ANOVA, analysis of variance.

    Article Snippet: Human ccRCC cell lines 786-O (cat. no. CL-0010), OSRC-2 (cat. no. CL-0177), Caki-1 (cat. no. CL-0052) and ACHN (cat. no. CL-0021), as well as non-malignant renal epithelial cells HK-2 (cat. no. CL-0109; all from Procell Life Science & Technology Co., Ltd.) and RPTEC/TERT1 (cat. no. CRL-4031; American Type Culture Collection), were used in the present study.

    Techniques: Activation Assay, Knockdown, CCK-8 Assay, Cell Counting, Control, Standard Deviation